Wait, It Costs How Much? Biotech Balances Optimism, Uncertainty For 2018 – Prosyscom Tech


Forbes

Wait, It Costs How Much? Biotech Balances Optimism, Uncertainty For 2018
Forbes
Many think it paid too much for Impact, and more are asking if, facing the future patent expiration of top drug Revlimid, the biotech giant needs to do a bigger deal. Many investors wanted them to buy Bluebird Bio, the gene therapy company. Regardless

Web Hosting

قالب وردپرس

Advertisements

You might also like More from author

Leave A Reply

Your email address will not be published.

%d bloggers like this: